Scientific deep-dive
GLP-1 Drugs and Low Blood Sugar: Who Is Actually at Risk
A GLP-1 alone is a poor cause of hypoglycemia, because it prompts insulin only when glucose is already high. The risk belongs to what it is taken alongside, and the label says one combination has never been evaluated.
If a GLP-1 is the only glucose-lowering drug you take, low blood sugar is an unlikely problem. These drugs prompt insulin release in response to glucose, so when glucose is not high they largely stop prompting. The risk arrives with what sits beside them. The Wegovy label is explicit about which company it keeps: put a sulfonylurea, or insulin, in the picture and hypoglycemia becomes more likely. It tells prescribers to consider cutting that other dose at the point the GLP-1 starts.[1] Metformin is not on that list; where it does overlap with a GLP-1 is covered in metformin and a GLP-1 together.
Why the mechanism matters here
Insulin, and the sulfonylureas the label groups as insulin secretagogues, lower blood glucose whether or not it needs lowering. That is what makes them capable of driving it too far down. A GLP-1 works differently: its effect on insulin secretion is glucose-dependent, which is the technical way of saying it largely stands down when glucose is normal.
The largest ongoing comparison of diabetes medicines, a living network meta-analysis in the BMJ updated at least twice a year, reflects that. It names sulfonylureas, insulin and DPP-4 inhibitors as probably increasing the risk of severe hypoglycemia.[2] GLP-1 receptor agonists are not in that list. In one trial, swapping basal-bolus insulin for a weekly semaglutide and insulin icodec injection cut serious lows by 88%. (Why a DPP-4 inhibitor such as Januvia is usually stopped when a GLP-1 starts is set out in Januvia and a GLP-1 together.)
Insulin and sulfonylureas lower blood glucose whether or not it needs lowering; a GLP-1 largely stands down when glucose is normal.
What the label actually counted
“Unlikely” is not “never”, and the label does not pretend otherwise. In its trial of adults who had type 2 diabetes alongside a BMI of 27 or above, hypoglycemia (defined as plasma glucose below 54 mg/dL) was reported in more patients on Wegovy than on placebo. One episode of severe hypoglycemia, meaning it required another person’s help, occurred in a treated patient, against none on placebo.[1]
One episode is a small number, but it is not zero, and it comes from the population where this matters: people who have diabetes as well as excess weight, and who are therefore likely to be on other glucose-lowering drugs already.
The combination the label has not tested
One sentence in the label is easy to read past. It states that the use of Wegovy in patients with type 1 diabetes, or in combination with insulin, has not been evaluated.[1]
That is not a contraindication or a warning against it. It means untested, and the difference matters because people reasonably assume that an approved drug has been studied in the combination they are personally taking. The sentence is about Wegovy’s own trials, though, not the whole class. Someone taking Wegovy with insulin is outside what those trials examined, whatever their prescriber has concluded is right for them. At diabetes doses the combination has been studied: the Ozempic and Mounjaro labels each report a trial that added the drug to basal insulin in type 2 diabetes, with hypoglycemia counted.[3][4]
What the label asks a prescriber to do
- Check glucose before starting, and during. For patients with diabetes the label asks for monitoring at both points, not just afterward.[1]
- Consider a smaller dose of the sulfonylurea or insulin from the day the GLP-1 begins. The label frames this as something to weigh when the GLP-1 starts, rather than a change to make after a low reading.[1]
- Teach the symptoms. The label asks prescribers to inform patients of the risk and educate them on the signs, which implies you should have been told and can ask if you were not.
Knowing it when it happens
Shakiness, sweating, a racing heart, sudden hunger, confusion, irritability or difficulty concentrating. During sleep it can show up as nightmares or damp sheets instead; see GLP-1s and nightmares. Severe episodes can progress to an inability to treat yourself, which is what the label means by requiring another person’s assistance. A racing heart without those other signs has other explanations on these drugs, covered in GLP-1 heart rate and palpitations. Because the labels list anxiety among these signs, an episode can be mistaken for a panic attack; see GLP-1s and anxiety.
There is a wrinkle specific to these drugs. GLP-1 medicines slow how quickly the stomach empties, which is also how quickly a fast-acting carbohydrate reaches the bloodstream. That does not change what you should do about a low reading, but it is a reason to raise the question with whoever manages your diabetes, since the usual timing assumptions may not hold. A fast long enough to matter changes that arithmetic, and the only place it has been studied is Ramadan. What the four Ramadan studies actually tested is narrower than it is usually reported to be.
Frequently Asked Questions
References
- 1.Novo Nordisk Inc. WEGOVY (semaglutide) — US Prescribing Information, Section 5.4 Hypoglycemia and Section 7.1 Drug Interactions (revised 06/2026) DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- 2.Nong K, Jeppesen BT, Shi Q, et al. Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis BMJ. 2025. PMID: 40813122.
- 3.Novo Nordisk Inc. OZEMPIC (semaglutide) injection: US Prescribing Information, Sections 6.1 and 14 (combination with basal insulin) DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
- 4.Eli Lilly and Company MOUNJARO (tirzepatide) injection: US Prescribing Information, Sections 6.1 and 14 (SURPASS-5, added to basal insulin) DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
Compare the sellers
Related research
Stopping Ozempic or Wegovy: Side Effects, Weight Regain and Keeping It Off
Stopping Ozempic or Wegovy causes no withdrawal syndrome on either label. Appetite returns as semaglutide clears over about five weeks, and a 2026 BMJ meta-analysis found regain of about 0.8 kg a month. What helps keep weight off, and what women should know.
10 min read
GLP-1 Drugs and Suicidal Thoughts: The Warning Came Off in 2026
In February 2026 the Suicidal Behavior and Ideation section was removed from the Wegovy, Zepbound and Saxenda labels, after three large studies looked for a signal and none found one.
7 min read
Exenatide (Byetta, Bydureon): The First GLP-1, Its Weight Loss and Where It Went
Exenatide, sold as Byetta and Bydureon BCise, was the first GLP-1 drug. It is approved only for type 2 diabetes, produces far less weight loss than semaglutide, and both brands are discontinued in the US. Its one generic is now listed as discontinued too.
10 min read
GLP-1 Drugs and Your Kidneys: Protective Over Years, Risky Over Days
Semaglutide cut the risk of kidney failure, a large drop in kidney function, or death from a kidney or cardiovascular cause by 24% over a median 3.4 years. The label also warns of acute kidney injury in people dehydrated by vomiting or diarrhea. Both are true.
7 min read
Injection Site Reactions: Where Semaglutide and Tirzepatide Really Differ
Semaglutide produced injection site reactions in 1.4% against 1% on placebo. Tirzepatide runs 6–8% against 2%. If you react on one and not the other, that is not your technique.
5 min read
GLP-1 Pancreatitis and Gallbladder Risk: What the Labels Counted
Two labeled warnings that are not the same kind of problem. Gallbladder disease tracks with rapid weight loss and is well counted; pancreatitis is rarer, was an exclusion criterion in the pivotal trials, and the database studies disagree.
12 min read
Where to get semaglutide online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
bmiMD
Starting below a standard dose, with microdose tiers
From $129/mo, prepaid
Get started →WellMedRx
Comparing compounded and brand GLP-1 plans with a published state list
From $49/mo
Get started →YourEra
From $99/mo
Get started →